Taysha Gene Therapies, Inc.
TSHA
$2.31
-$0.07-2.94%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -32.51% | -43.90% | -62.33% | -53.57% | -27.52% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -32.51% | -43.90% | -62.33% | -53.57% | -27.52% |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -32.51% | -43.90% | -62.33% | -53.57% | -27.52% |
| SG&A Expenses | 15.16% | 3.20% | -7.78% | 18.33% | -19.05% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -14.48% | 13.16% | 12.11% | -13.06% | 30.45% |
| Operating Income | 11.96% | -26.18% | -34.71% | 8.92% | -46.93% |
| Income Before Tax | 10.52% | -139.35% | 78.20% | 14.92% | -36.54% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 10.52% | -139.35% | 78.20% | 14.92% | -36.54% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 10.52% | -139.35% | 78.20% | 14.92% | -36.54% |
| EBIT | 11.96% | -26.18% | -34.71% | 8.92% | -46.93% |
| EBITDA | 11.94% | -27.20% | -35.70% | 8.96% | -47.92% |
| EPS Basic | 23.17% | -130.88% | 89.77% | 76.52% | 62.67% |
| Normalized Basic EPS | 25.40% | -121.82% | 91.66% | 77.98% | 64.27% |
| EPS Diluted | 23.17% | -130.88% | 89.77% | 76.52% | 62.67% |
| Normalized Diluted EPS | 25.40% | -121.82% | 91.66% | 77.98% | 64.27% |
| Average Basic Shares Outstanding | 16.46% | 27.44% | 113.06% | 262.40% | 265.55% |
| Average Diluted Shares Outstanding | 16.46% | 27.44% | 113.06% | 262.40% | 265.55% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |